Matica Bio Launches Integrated Korea IIT Platform to Accelerate Global Cell and Gene Therapy Development
核心洞察
Matica Biotechnology (搜索) launched the Accelerated Matica Korea IIT Integrated Platform Solution to streamline investigator-initiated trials for cell and gene therapies.
The platform combines U.S.-based GMP manufacturing with Korea's clinical infrastructure, offering a single point of contact for global biotech companies.
Korea is positioned as a strategic alternative to China, Australia, and Europe for IITs amid rising geopolitical tensions and supply chain diversification.
Matica Biotechnology (搜索), a U.S.-based viral vector contract development and manufacturing organization (CDMO) and subsidiary of Korea's Cha Biotech (搜索), has launched the Accelerated Matica Korea IIT Integrated Platform Solution, a collaborative framework designed to accelerate investigator-initiated trials (IITs) and early translational development programs for global cell and gene therapy innovators.
The launch, announced on June 18, 2026, comes at a pivotal moment as global drugmakers increasingly diversify manufacturing and clinical development away from China amid rising geopolitical tensions. The integrated platform combines Korea's globally recognized clinical execution capabilities with Matica Bio's U.S.-based GMP manufacturing, process development, analytical development, and translational CMC expertise.
"Global demand for high quality, globally accepted clinical data continues to accelerate, particularly in advanced therapies," said Paul Kim, Chief Executive Officer of Matica Bio. "Korea has emerged as one of the most strategically positioned environments for investigator initiated and translational clinical studies due to its clinical excellence, operational efficiency, and strong regulatory credibility."
A Strategic Alternative for Global Biotech
The platform positions Korea as a strategic destination for IITs at a time when China, Australia, and Europe are often the default choices. Cha Biotech (搜索), in collaboration with Matica Biotechnology (搜索), initially launched the program in June and plans to hold an online seminar titled "South Korea IIT: The Emerging Global Alternative for Accelerating Cell & Gene Therapy Development" to highlight Korea's advantages.
The webinar will compare the strengths of Korea, China, Australia, and Europe across six criteria: development speed, data quality, manufacturing-clinical integration, regulatory readiness, supply chain stability, and long-term commercialization potential. The company emphasizes that IIT strategies should be assessed based on multiple development factors rather than cost alone, and that geographic selection should be a strategic decision rather than a one-size-fits-all choice.
Integrated Platform Capabilities
The Matica Korea IIT Integrated Platform Solution is designed to support investigator-initiated trials for cell and gene therapies, translational oncology programs and proof-of-concept studies, integrated GMP manufacturing and clinical development strategies, IND-enabling CMC and scalable development pathways, and flexible collaboration models for hospitals, academic institutions, and emerging biotech companies.
Unlike fragmented development approaches that often require multiple disconnected vendors and lengthy coordination timelines, the integrated platform provides a streamlined framework connecting Korean clinical execution with Matica Bio's advanced manufacturing and technical capabilities.
"Our integrated platform is designed to reduce complexity for innovators by aligning clinical execution, CMC strategy, and manufacturing support within a single collaborative framework," Kim added. "This enables companies to move faster from translational research into globally scalable clinical development."
Korea's Clinical Ecosystem Advantages
The platform leverages several core advantages of the Korean advanced therapy ecosystem, including globally trusted clinical execution and digital hospital infrastructure, strong investigator expertise across cell and gene therapy studies, efficient coordination between hospitals and manufacturing partners, and clinical datasets suitable for global regulatory pathways.
Korea's established Good Clinical Practice (GCP) infrastructure, experienced principal investigators, advanced translational medicine ecosystem, and strong regulatory alignment with FDA, EMA, and PMDA expectations position the country as an emerging hub for investigator-driven studies. Korea IITs also benefit from experienced CRO support for well-organized clinical data, accurate donor eligibility verification, fast patient enrollment, and relatively efficient clinical review timelines from the MFDS.
The platform also offers strong intellectual property protection through U.S.-based manufacturing support. Matica Bio will support programs across the full development continuum, including technology transfer, IND-enabling CMC strategies, process optimization, comparability support, clinical material manufacturing, and scalable development planning aligned with future global regulatory pathways.
Streamlining Global Development
Through the integrated platform, Matica Bio provides an integrated U.S.-to-Korea development pathway designed specifically for IIT and early clinical stage advanced therapy programs. The framework enables Korean investigators and global biotech innovators to leverage Korea's highly efficient clinical and translational environment while accessing Matica Bio's U.S.-based GMP manufacturing and regulatory support capabilities.
According to the company, the integrated approach can reduce project management burdens, shorten development timelines, and improve the efficiency of clinical development strategies. It streamlines coordination between manufacturing operations in the U.S. and clinical execution in Korea to rapidly generate high-quality clinical data.
"Through the Matica K-IIT Program, the company aims to support international biotech companies entering Korea while strengthening the country's position as a leading clinical development hub for advanced therapies in Asia," said a Cha Biotech (搜索) official.